<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VASOTEC - enalapril maleate tablet </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>TABLETS VASOTEC®  (ENALAPRIL MALEATE)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Rx Only</p>
<p>
 
</p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<h1>Boxed Warning section</h1>
<p class="First"></p>
<p><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></p>
<p>1.</p>
<p><span class="Bold">When pregnancy is detected, discontinue VASOTEC<span class="Sup">®</span> as soon as possible.</span></p>
<p>2.</p>
<p><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. See <a href="#warnings_fetal">Warnings: Fetal Toxicity</a></span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>VASOTEC<span class="Sup">®</span> (Enalapril Maleate) is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin converting enzyme inhibitor, enalaprilat. Enalapril maleate is chemically described as (S)-1-[<span class="Italics">N</span>-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline, (<span class="Italics">Z</span>)-2-butenedioate salt (1:1). Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">28</span>N<span class="Sub">2</span>O<span class="Sub">5</span>•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span>, and its structural formula is:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da4704d6-dc9e-4539-809e-4bdbc898043a&amp;name=MM1.jpg"></p>
<p>Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol.</p>
<p>Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin converting enzyme inhibitor.</p>
<p>Enalapril maleate is supplied as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets for oral administration. In addition to the active ingredient enalapril maleate, each tablet contains the following inactive ingredients: lactose, magnesium stearate, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, and starch. The 10 mg and 20 mg tablets also contain iron oxides.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p><span class="Italics">Mechanism of Action</span></p>
<p>Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive patients treated with VASOTEC alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2 mEq/L were observed. In patients treated with VASOTEC plus a thiazide diuretic, there was essentially no change in serum potassium (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>). Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.</p>
<p>ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of VASOTEC remains to be elucidated.</p>
<p>While the mechanism through which VASOTEC lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, VASOTEC is antihypertensive even in patients with low-renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Although VASOTEC was antihypertensive in all races studied, black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to enalapril monotherapy than non-black patients.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pharmacokinetics and Metabolism</span></p>
<p>Following oral administration of VASOTEC, peak serum concentrations of enalapril occur within about one hour. Based on urinary recovery, the extent of absorption of enalapril is approximately 60 percent. Enalapril absorption is not influenced by the presence of food in the gastrointestinal tract. Following absorption, enalapril is hydrolyzed to enalaprilat, which is a more potent angiotensin converting enzyme inhibitor than enalapril; enalaprilat is poorly absorbed when administered orally. Peak serum concentrations of enalaprilat occur three to four hours after an oral dose of enalapril maleate. Excretion of VASOTEC is primarily renal. Approximately 94 percent of the dose is recovered in the urine and feces as enalaprilat or enalapril. The principal components in urine are enalaprilat, accounting for about 40 percent of the dose, and intact enalapril. There is no evidence of metabolites of enalapril, other than enalaprilat.</p>
<p>The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE. The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours. The disposition of enalapril and enalaprilat in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. With glomerular filtration rate ≤30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases and time to steady state may be delayed. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>). Enalaprilat is dialyzable at the rate of 62 mL/min.</p>
<p>Studies in dogs indicate that enalapril crosses the blood-brain barrier poorly, if at all; enalaprilat does not enter the brain. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of <span class="Sup">14</span>C-enalapril maleate. Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pharmacodynamics and Clinical Effects</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>Administration of VASOTEC to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> of severity ranging from mild to severe results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> is therefore infrequent, although it might be anticipated in volume-depleted patients (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
<p>In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours.</p>
<p>At recommended doses, antihypertensive effects have been maintained for at least 24 hours. In some patients the effects may diminish toward the end of the dosing interval (see <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>In some patients achievement of optimal blood pressure reduction may require several weeks of therapy.</p>
<p>The antihypertensive effects of VASOTEC have continued during long term therapy. Abrupt withdrawal of VASOTEC has not been associated with a rapid increase in blood pressure.</p>
<p>In hemodynamic studies in patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and little or no change in heart rate. Following administration of VASOTEC, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span>.</p>
<p>When given together with thiazide-type diuretics, the blood pressure lowering effects of VASOTEC are approximately additive.</p>
<p>In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC (see <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a></span>).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></p>
<p>In trials in patients treated with digitalis and diuretics, treatment with enalapril resulted in decreased systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, blood pressure, pulmonary capillary wedge pressure and heart size, and increased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and exercise tolerance. Heart rate was unchanged or slightly reduced, and mean <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> was unchanged or increased. There was a beneficial effect on severity of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> as measured by the New York Heart Association (NYHA) classification and on symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. Hemodynamic effects were observed after the first dose, and appeared to be maintained in uncontrolled studies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> were observed in placebo-controlled studies lasting from eight weeks to over one year.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, Mortality Trials</span></p>
<p>In a multicenter, placebo-controlled clinical trial, 2,569 patients with all degrees of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤35 percent were randomized to placebo or enalapril and followed for up to 55 months (SOLVD-Treatment). Use of enalapril was associated with an 11 percent reduction in all-cause mortality and a 30 percent reduction in hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Diseases that excluded patients from enrollment in the study included severe stable angina (&gt;2 attacks/day), hemodynamically significant valvular or outflow tract obstruction, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (creatinine &gt;2.5 mg/dL), cerebral vascular disease (e.g., significant <span class="product-label-link" type="condition" conceptid="4153380" conceptname="Disorder of carotid artery">carotid artery disease</span>), advanced pulmonary disease, malignancies, active <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present.</p>
<p>A second multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤35% and no history of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, were randomized to placebo (n=2117) or enalapril (n=2111) and followed for up to 5 years. The majority of patients in the SOLVD-Prevention trial had a history of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>. A history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was present in 80 percent of patients, current <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> in 34 percent, and a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32% fewer first hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and 32% fewer total <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect.</p>
<p>The SOLVD-Prevention trial was not designed to determine whether treatment of asymptomatic patients with low <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> would be superior, with respect to preventing hospitalization, to closer follow-up and use of enalapril at the earliest sign of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. However, under the conditions of follow-up in the SOLVD-Prevention trial (every 4 months at the study clinic; personal physician as needed), 68% of patients on placebo who were hospitalized for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> had no prior symptoms recorded which would have signaled initiation of treatment.</p>
<p>The SOLVD-Prevention trial was also not designed to show whether enalapril modified the progression of underlying heart disease.</p>
<p>In another multicenter, placebo-controlled trial (CONSENSUS) limited to patients with NYHA Class IV <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and radiographic evidence of <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, use of enalapril was associated with improved survival. The results are shown in the following table.</p>
<table width="60%">
<col span="1" width="29%">
<col span="1" width="16%">
<col span="1" width="15%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"><span class="Bold">  </span></th>
<th colspan="2"><span class="Bold">SURVIVAL (%)</span></th>
</tr>
<tr>
<th colspan="1"><span class="Bold">  </span></th>
<th colspan="1"><span class="Bold">Six Months</span></th>
<th colspan="1"><span class="Bold">One Year</span></th>
</tr>
<tr>
<td><p class="First">VASOTEC (n=127)</p></td>
<td><p class="First">74</p></td>
<td><p class="First">64</p></td>
</tr>
<tr class="Last">
<td><p class="First">Placebo (n=126)</p></td>
<td><p class="First">56</p></td>
<td><p class="First">48</p></td>
</tr>
</tbody>
</table>
<p>In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving digitalis, diuretics or both.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Clinical Pharmacology in Pediatric Patients</span></p>
<p>A multiple dose pharmacokinetic study was conducted in 40 hypertensive male and female pediatric patients aged 2 months to ≤16 years following daily oral administration of 0.07 to 0.14 mg/kg enalapril maleate. At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose. Conversion of enalapril to enalaprilat was in the range of 63-76%. The overall results of this study indicate that the pharmacokinetics of enalapril in hypertensive children aged 2 months to ≤16 years are consistent across the studied age groups and consistent with pharmacokinetic historic data in healthy adults.</p>
<p>In a clinical study involving 110 hypertensive pediatric patients 6 to 16 years of age, patients who weighed &lt;50 kg received either 0.625, 2.5 or 20 mg of enalapril daily and patients who weighed ≥50 kg received either 1.25, 5, or 40 mg of enalapril daily. Enalapril administration once daily lowered trough blood pressure in a dose-dependent manner. The dose-dependent antihypertensive efficacy of enalapril was consistent across all subgroups (age, Tanner stage, gender, race). However, the lowest doses studied, 0.625 mg and 1.25 mg, corresponding to an average of 0.02 mg/kg once daily, did not appear to offer consistent antihypertensive efficacy. In this study, VASOTEC was generally well tolerated.</p>
<p>In the above pediatric studies, enalapril maleate was given as tablets of VASOTEC and for those children and infants who were unable to swallow tablets or who required a lower dose than is available in tablet form, enalapril was administered in a suspension formulation (see <span class="Italics"><a href="#Preparation_of_Suspension">Preparation of Suspension</a></span> under <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>VASOTEC is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></p>
<p>VASOTEC is indicated for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization (see <span class="Bold"><a href="#clinical_pharmacology_trials">CLINICAL PHARMACOLOGY,	<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, Mortality Trials</a></span> for details and limitations of survival trials).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span></span></p>
<p>In clinically stable asymptomatic patients with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤35 percent), VASOTEC decreases the rate of development of overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and decreases the incidence of hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (see <span class="Bold"><a href="#clinical_pharmacology_trials">CLINICAL PHARMACOLOGY, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, Mortality Trials</a></span> for details and limitations of survival trials).</p>
<p>In using VASOTEC consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
<p>In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> compared to non-blacks (see <span class="Bold"><a href="#warnings_angioedema">WARNINGS, Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>Do not coadminister aliskiren with VASOTEC in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (see <span class="Bold"><a href="#_Ref">PRECAUTIONS, Drug Interactions</a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p><span class="Italics">Anaphylactoid and Possibly Related Reactions</span></p>
<p>Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including VASOTEC) may be subject to a variety of adverse reactions, some of them serious.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="Italics">Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including VASOTEC. This may occur at any time during treatment. In such cases VASOTEC should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> may be fatal. <span class="Bold">Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided</span> (see <span class="Bold"><a href="#adverse_reactions">ADVERSE REACTIONS</a></span>).</p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="Italics">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span></span> Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been reported in patients treated with ACE inhibitors.  These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal.  The <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor.  Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> should be included in the differential diagnosis of patients on ACE inhibitors presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p>Patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> unrelated to ACE inhibitor therapy may be at increased risk of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> while receiving an ACE inhibitor (see also <span class="Bold"><a href="#indications_usage">INDICATIONS AND USAGE</a></span> and <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during desensitization</span></p>
<p>Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during membrane exposure</span></p>
<p><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></p>
<p>Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is rare in uncomplicated hypertensive patients treated with VASOTEC alone. Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> given VASOTEC commonly have some reduction in blood pressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy (see <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>). Patients at risk for excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, sometimes associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rarely with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, include those with the following conditions or characteristics: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, high dose diuretic therapy, recent intensive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or increase in diuretic dose, renal dialysis, or severe volume and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> of any etiology. It may be advisable to eliminate the diuretic (except in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), reduce the diuretic dose or increase salt intake cautiously before initiating therapy with VASOTEC in patients at risk for excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> who are able to tolerate such adjustments (see <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a></span> and <span class="Bold"><a href="#adverse_reactions">ADVERSE REACTIONS</a></span>). In patients at risk for excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> could result in a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>If excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of VASOTEC, which usually can be given without difficulty once the blood pressure has stabilized. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> develops, a dose reduction or discontinuation of VASOTEC or concomitant diuretic may be necessary.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span></p>
<p>Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, rarely in uncomplicated patients but more frequently in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> at similar rates. Marketing experience has revealed cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be considered.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></span></p>
<p>Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and (sometimes) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Pregnancy category D</span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue Vasotec as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue VASOTEC, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to VASOTEC for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. [<span class="Italics">see </span><span class="Bold"><a href="#PEDIATRIC">PRECAUTIONS, Pediatric use</a></span>]</p>
<p>No teratogenic effects of enalapril were seen in studies of pregnant rats and rabbits. On a body surface area basis, the doses used were 57 times and 12 times, respectively, the maximum recommended human daily dose (MRHDD).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p><span class="Italics">General</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">Aortic Stenosis</span>/<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">Hypertrophic Cardiomyopathy</span>:</span></p>
<p>As with all vasodilators, enalapril should be given with caution to patients with obstruction in the outflow tract of the left ventricle.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>:</span></p>
<p>As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including VASOTEC, may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and rarely with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <span class="Bold"><a href="#_Ref">PRECAUTIONS, Drug Interactions</a></span>).</p>
<p>In clinical studies in hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.</p>
<p>Some patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when VASOTEC has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction and/or discontinuation of the diuretic and/or VASOTEC may be required.</p>
<p><span class="Bold">Evaluation of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should always include assessment of renal function</span> (see <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>:</span></p>
<p>Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials. In most cases these were isolated values which resolved despite continued therapy. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. In clinical trials in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> was observed in 3.8 percent of patients but was not a cause for discontinuation.</p>
<p>Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with VASOTEC (see <span class="Italics"><a href="#precautions_drug_interactions">Drug Interactions</a></span>).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>:</span></p>
<p>Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be considered in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Surgery/Anesthesia:</span></p>
<p>In patients undergoing major surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, enalapril may block angiotensin II formation secondary to compensatory renin release. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Information for Patients</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</span></p>
<p>Patients should be cautioned to report <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, especially during the first few days of therapy. If actual <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. All patients should be cautioned that excessive perspiration and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> because of reduction in fluid volume. Other causes of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> such as <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may also lead to a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>; patients should be advised to consult with the physician.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>:</span></p>
<p>Patients should be told not to use salt substitutes containing potassium without consulting their physician.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>:</span></p>
<p>Patients should be told to report promptly any indication of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) which may be a sign of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pregnancy:</span></p>
<p>Female patients of childbearing age should be told about the consequences of exposure to VASOTEC during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
<p>NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Drug Interactions</span></p>
<p>
 
</p>
<p></p>
<p>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on VASOTEC and other agents that affect the RAS.</p>
<p>Do not coadminister aliskiren with VASOTEC in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with VASOTEC in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;60 mL/min).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> — Patients on Diuretic Therapy:</span></p>
<p>Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Agents Causing Renin Release:</span></p>
<p>The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</span></p>
<p>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving enalapril and NSAID therapy. </p>
<p>In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Other Cardiovascular Agents:</span></p>
<p>VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Agents Increasing Serum Potassium:</span></p>
<p>VASOTEC attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, they should be used with caution and with frequent monitoring of serum potassium. Potassium sparing agents should generally not be used in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> receiving VASOTEC.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Lithium:</span></p>
<p><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Gold:</span></p>
<p>Nitritoid reactions (symptoms include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></p>
<p>There was no evidence of a tumorigenic effect when enalapril was administered for 106 weeks to male and female rats at doses up to 90 mg/kg/day or for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively. These doses are 26 times (in rats and female mice) and 13 times (in male mice) the maximum recommended human daily dose (MRHDD) when compared on a body surface area basis.</p>
<p>Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with <span class="Italics">E. coli</span>, sister chromatid exchange with cultured mammalian cells, and the micronucleus test with mice, as well as in an <span class="Italics">in vivo</span> cytogenic study using mouse bone marrow.</p>
<p>There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril (26 times the MRHDD when compared on a body surface area basis).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pregnancy</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Nursing Mothers</span></p>
<p>Enalapril and enalaprilat have been detected in human breast milk. Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue VASOTEC, taking into account the importance of the drug to the mother.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pediatric Use</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Neonates with a history of in utero exposure to VASOTEC:</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfustions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.</p>
<p>Antihypertensive effects of VASOTEC have been established in hypertensive pediatric patients age 1 month to 16 years. Use of VASOTEC in these age groups is supported by evidence from adequate and well-controlled studies of VASOTEC in pediatric and adult patients as well as by published literature in pediatric patients (see <span class="Bold"><a href="#clinical_pharmacology_pediatric">CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients</a></span> and <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>VASOTEC is not recommended in neonates and in pediatric patients with glomerular filtration rate &lt;30 mL/min/1.73 m<span class="Sup">2</span>, as no data are available.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>VASOTEC has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. VASOTEC has been found to be generally well tolerated in controlled clinical trials involving 2987 patients. For the most part, adverse experiences were mild and transient in nature. In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and in 5.7 percent of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. In patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> the overall percentage of patients treated with VASOTEC reporting adverse experiences was comparable to placebo.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span></span></p>
<p>Adverse experiences occurring in greater than one percent of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> treated with VASOTEC in controlled clinical trials are shown below. In patients treated with VASOTEC, the maximum duration of therapy was three years; in placebo treated patients the maximum duration of therapy was 12 weeks.</p>
<table width="60%">
<col span="1" width="24%">
<col span="1" width="22%">
<col span="1" width="15%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"><span class="Bold">  </span></th>
<th colspan="1">
<span class="Bold">VASOTEC</span><br><span class="Bold">(n=2314)</span><br><span class="Bold">Incidence</span><br><span class="Bold">(discontinuation)</span>
</th>
<th colspan="1">
<span class="Bold">Placebo</span><br><span class="Bold">(n=230)</span><br><span class="Bold">Incidence</span>
</th>
</tr>
<tr>
<td><p class="First"><span class="Italics">Body As A Whole</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td><p class="First">3.0 (&lt;0.1)</p></td>
<td><p class="First">2.6</p></td>
</tr>
<tr>
<td><p class="First">  Orthostatic Effects</p></td>
<td><p class="First">1.2 (&lt;0.1)</p></td>
<td><p class="First">0.0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td><p class="First">1.1 (0.1)</p></td>
<td><p class="First">0.9</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Digestive</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td><p class="First">1.4 (&lt;0.1)</p></td>
<td><p class="First">1.7</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">1.4 (0.2)</p></td>
<td><p class="First">1.7</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Nervous/Psychiatric</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">5.2 (0.3)</p></td>
<td><p class="First">9.1</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">4.3 (0.4)</p></td>
<td><p class="First">4.3</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Respiratory</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td><p class="First">1.3 (0.1)</p></td>
<td><p class="First">0.9</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Skin</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr class="Last">
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td><p class="First">1.4 (0.4)</p></td>
<td><p class="First">0.4</p></td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span></span></p>
<p>Adverse experiences occurring in greater than one percent of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> treated with VASOTEC are shown below. The incidences represent the experiences from both controlled and uncontrolled clinical trials (maximum duration of therapy was approximately one year). In the placebo treated patients, the incidences reported are from the controlled trials (maximum duration of therapy is 12 weeks). The percentage of patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (NYHA Class IV) was 29 percent and 43 percent for patients treated with VASOTEC and placebo, respectively.</p>
<table width="75%">
<col span="1" width="30%">
<col span="1" width="27%">
<col span="1" width="18%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"><span class="Bold">  </span></th>
<th colspan="1">
<span class="Bold">VASOTEC</span><br><span class="Bold">(n=673)</span><br><span class="Bold">Incidence</span><br><span class="Bold">(discontinuation)</span>
</th>
<th colspan="1">
<span class="Bold">Placebo</span><br><span class="Bold">(n=339)</span><br><span class="Bold">Incidence</span>
</th>
</tr>
<tr>
<td><p class="First"><span class="Italics">Body As A Whole</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First">Orthostatic Effects</p></td>
<td><p class="First">2.2 (0.1)</p></td>
<td><p class="First">0.3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></p></td>
<td><p class="First">2.2 (0.1)</p></td>
<td><p class="First">0.9</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td><p class="First">2.1 (0.0)</p></td>
<td><p class="First">2.1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td><p class="First">1.8 (0.0)</p></td>
<td><p class="First">1.8</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td><p class="First">1.6 (0.4)</p></td>
<td><p class="First">2.1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td><p class="First">1.6 (0.1)</p></td>
<td><p class="First">0.3</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Cardiovascular</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td><p class="First">6.7 (1.9)</p></td>
<td><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></p></td>
<td><p class="First">1.6 (0.1)</p></td>
<td><p class="First">0.3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span></p></td>
<td><p class="First">1.5 (0.1)</p></td>
<td><p class="First">1.8</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></p></td>
<td><p class="First">1.2 (0.3)</p></td>
<td><p class="First">1.8</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Digestive</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td><p class="First">2.1 (0.1)</p></td>
<td><p class="First">1.2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">1.3 (0.1)</p></td>
<td><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td><p class="First">1.3 (0.0)</p></td>
<td><p class="First">0.9</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Nervous/Psychiatric</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">7.9 (0.6)</p></td>
<td><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">1.8 (0.1)</p></td>
<td><p class="First">0.9</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td><p class="First">1.6 (0.1)</p></td>
<td><p class="First">1.2</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Respiratory</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td><p class="First">2.2 (0.0)</p></td>
<td><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td><p class="First">1.3 (0.0)</p></td>
<td><p class="First">0.9</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td><p class="First">1.3 (0.1)</p></td>
<td><p class="First">0.4</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td><p class="First">1.0 (0.0)</p></td>
<td><p class="First">2.4</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Skin</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td><p class="First">1.3 (0.0)</p></td>
<td><p class="First">2.4</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Urogenital</span></p></td>
<td><p class="First">  </p></td>
<td><p class="First">  </p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td><p class="First">1.3 (0.0)</p></td>
<td><p class="First">2.4</p></td>
</tr>
</tbody>
</table>
<p>Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in 0.5 to 1.0 percent of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in clinical trials are listed below and, within each category, are in order of decreasing severity.</p>
<p><span class="Italics">Body As A Whole:</span> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> (see <span class="Bold"><a href="#warnings_anaphylactoid">WARNINGS, Anaphylactoid and Possibly Related Reactions</a></span>).</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, possibly secondary to excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in high risk patients (see <span class="Bold"><a href="#warnings_hypotension">WARNINGS, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></span>); <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>; <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>; rhythm disturbances including <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, Raynaud's phenomenon.</p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (hepatocellular [proven on rechallenge] or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>) (see <span class="Bold"><a href="#warnings_hepatic_failure">WARNINGS, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></a></span>), <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Italics">Hematologic:</span> Rare cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>.</p>
<p><span class="Italics">Nervous/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>), dream abnormality.</p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> and <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, pulmonary infiltrates, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span>, <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">anosmia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, tearing.</p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, renal dysfunction (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span> and <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>), <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
<p><span class="Italics">Miscellaneous:</span> A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>/<span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4157025" conceptname="Serositis">serositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and other dermatologic manifestations.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> has been reported in patients receiving VASOTEC, with an incidence higher in black than in non-black patients. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> may be fatal. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with VASOTEC should be discontinued and appropriate therapy instituted immediately (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</span> In the hypertensive patients, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in 0.9 percent and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurred in 0.5 percent of patients following the initial dose or during extended therapy. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was a cause for discontinuation of therapy in 0.1 percent of hypertensive patients. In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in 6.7 percent and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurred in 2.2 percent of patients. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was a cause for discontinuation of therapy in 1.9 percent of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>:</span> See <span class="Bold"><a href="#precautions_cough">PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></a></span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pediatric Patients</span></p>
<p>The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Clinical Laboratory Test Findings</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Serum Electrolytes:</span></p>
<p><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>), <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Creatinine, Blood Urea Nitrogen:</span></p>
<p>In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.2 percent of patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> treated with VASOTEC alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span> (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>). In patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> who were also receiving diuretics with or without digitalis, increases in blood urea nitrogen or serum creatinine, usually reversible upon discontinuation of VASOTEC and/or other concomitant diuretic therapy, were observed in about 11 percent of patients. Increases in blood urea nitrogen or creatinine were a cause for discontinuation in 1.2 percent of patients.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Hematology:</span></p>
<p>Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g percent and 1.0 vol percent, respectively) occur frequently in either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> patients treated with VASOTEC but are rarely of clinical importance unless another cause of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> coexists. In clinical trials, less than 0.1 percent of patients discontinued therapy due to <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, including cases of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in patients with G-6-PD deficiency, has been reported; a causal relationship to enalapril cannot be excluded.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Liver Function Tests</span></p>
<p>Elevations of liver enzymes and/or serum bilirubin have occurred (see <span class="Bold"><a href="#warnings_hepatic_failure">WARNINGS, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>Limited data are available in regard to overdosage in humans.</p>
<p>Single oral doses of enalapril above 1,000 mg/kg and ≥1,775 mg/kg were associated with lethality in mice and rats, respectively.</p>
<p>The most likely manifestation of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, for which the usual treatment would be intravenous infusion of normal saline solution.</p>
<p>Enalaprilat may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis (see <span class="Bold"><a href="#warnings_anaphylactic_reactions">WARNINGS, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during membrane exposure</a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>In patients who are currently being treated with a diuretic, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occasionally may occur following the initial dose of VASOTEC. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>). If the patient's blood pressure is not controlled with VASOTEC alone, diuretic therapy may be resumed.</p>
<p>If the diuretic cannot be discontinued an initial dose of 2.5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a></span>).</p>
<p>The recommended initial dose in patients not on diuretics is 5 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 10 to 40 mg per day administered in a single dose or two divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, an increase in dosage or twice daily administration should be considered. If blood pressure is not controlled with VASOTEC alone, a diuretic may be added. Concomitant administration of VASOTEC with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Dosage Adjustment in Hypertensive Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The usual dose of enalapril is recommended for patients with a creatinine clearance &gt;30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance ≤30 mL/min (serum creatinine ≥3 mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.</p>
<table width="60%">
<col span="1" width="23%">
<col span="1" width="22%">
<col span="1" width="15%">
<tbody class="Headless">
<tr class="First">
<th colspan="1"><span class="Bold">Renal Status</span></th>
<th colspan="1">
<span class="Bold">Creatinine-</span><br><span class="Bold">Clearance</span><br><span class="Bold">mL/min</span>
</th>
<th colspan="1">
<span class="Bold">Initial Dose</span><br><span class="Bold">mg/day</span>
</th>
</tr>
<tr>
<td><p class="First">Normal Renal Function</p></td>
<td><p class="First">&gt;80 mL/min</p></td>
<td><p class="First">5 mg</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First">Mild Impairment</p></td>
<td><p class="First">≤80 &gt;30 mL/min</p></td>
<td><p class="First">5 mg</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr>
<td><p class="First">Moderate to Severe<br>Impairment</p></td>
<td><p class="First">≤30 mL/min</p></td>
<td><p class="First">2.5 mg</p></td>
</tr>
<tr><td><p class="First">  </p></td></tr>
<tr class="Last">
<td><p class="First">Dialysis Patients<a href="#footnote-1">*</a></p></td>
<td></td>
<td><p class="First">2.5 mg on<br>dialysis days<a href="#footnote-2">†</a></p></td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></p>
<p>VASOTEC is indicated for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, usually in combination with diuretics and digitalis. In the placebo-controlled studies that demonstrated improved survival, patients were titrated as tolerated up to 40 mg, administered in two divided doses.</p>
<p>The recommended initial dose is 2.5 mg. The recommended dosing range is 2.5 to 20 mg given twice a day. Doses should be titrated upward, as tolerated, over a period of a few days or weeks. The maximum daily dose administered in clinical trials was 40 mg in divided doses.</p>
<p>After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a></span>). If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The appearance of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span></span></p>
<p>In the trial that demonstrated efficacy, patients were started on 2.5 mg twice daily and were titrated as tolerated to the targeted daily dose of 20 mg (in divided doses).</p>
<p>After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a></span>). If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The appearance of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Dosage Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> who have <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see <span class="Bold"><a href="#dosage_administration_heart_failure">DOSAGE AND ADMINISTRATION, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a></span>, <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a></span>). The dose may be increased to 2.5 mg b.i.d., then 5 mg b.i.d. and higher as needed, usually at intervals of four days or more if at the time of dosage adjustment there is not excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or significant deterioration of renal function. The maximum daily dose is 40 mg.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pediatric Hypertensive Patients</span></p>
<p>The usual recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. Dosage should be adjusted according to blood pressure response. Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients (see <span class="Bold"><a href="#clinical_pharmacology_pediatric">CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients</a></span>).</p>
<p>VASOTEC is not recommended in neonates and in pediatric patients with glomerular filtration rate &lt;30 mL/min/1.73 m<span class="Sup">2</span>, as no data are available.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Preparation of Suspension (for 200 mL of a 1.0 mg/mL suspension)</span></p>
<p>Add 50 mL of Bicitra<span class="Sup">®</span><a href="#footnote-1">1</a> to a polyethylene terephthalate (PET) bottle containing ten 20 mg tablets of VASOTEC and shake for at least 2 minutes. Let concentrate stand for 60 minutes. Following the 60-minute hold time, shake the concentrate for an additional minute. Add 150 mL of Ora-Sweet SF™<a href="#footnote-2">2</a> to the concentrate in the PET bottle and shake the suspension to disperse the ingredients. The suspension should be refrigerated at 2-8°C (36-46°F) and can be stored for up to 30 days. Shake the suspension before each use.</p>
<p><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a></p>
<p><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a></p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>See </dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>Dosage on nondialysis days should be adjusted depending on the blood pressure response.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>Registered trademark of Alza Corporation</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>Trademark of Paddock Laboratories, Inc.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>VASOTEC Tablets, 2.5 mg, are white, oval shaped tablet imprinted with "VASO 2.5" and scored on one side and scored on the other.<br>They are supplied as follows:<br>NDC 0187-0140-30 bottles of 30 (with desiccant)<br>NDC 0187-0140-90 unit of use bottles of 90 (with desiccant)</p>
<p>VASOTEC Tablets, 5 mg, are white, rounded triangle shaped tablet imprinted with "VASO 5" on one side and scored on the other.<br>They are supplied as follows:<br>NDC 0187-0141-30 bottles of 30 (with desiccant)<br>NDC 0187-0141-90 unit of use bottles of 90 (with desiccant)<br>NDC 0187-0141-10 bottles of 1,000 (with desiccant)</p>
<p>VASOTEC Tablets, 10 mg, are rust red, rounded triangle shaped tablet imprinted with "VASO 10" on one side and scored on the other. <br>They are supplied as follows:<br>NDC 0187-0142-30 bottles of 30 (with desiccant)<br>NDC 0187-0142-90 unit of use bottles of 90 (with desiccant)<br>NDC 0187-0142-10 bottles of 1,000 (with desiccant)</p>
<p>VASOTEC Tablets, 20 mg, are peach, rounded triangle shaped tablet imprinted with "VASO 20" on one side and scored on the other.<br>They are supplied as follows:<br>NDC 0187-0143-30 bottles of 30 (with desiccant)<br>NDC 0187-0143-90 unit of use bottles of 90 (with desiccant)<br>NDC 0187-0143-10 bottles of 1,000 (with desiccant)</p>
<p>
 
</p>
<p></p>
<p>Storage</p>
<p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. </p>
<p>Keep container tightly closed.</p>
<p>Protect from moisture.</p>
<p>Dispense in a tight container as per USP, if product package is subdivided.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Vasotec<span class="Sup">®</span> is a registered trademark of Valeant International Bermuda.</p>
<p>Manufactured in Canada by:<br>Valeant Pharmaceuticals International, Inc.<br>Steinbach, MB R5G 1Z7 Canada</p>
<p>For:<br>Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807 USA</p>
<p>Rev. 12/2014</p>
<p>9383001</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Vasotec </p>
<p><br></p>
<p>GENERIC: Enalapril Maleate</p>
<p><br></p>
<p>DOSAGE: TABLET</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 61786-168-02</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>Enalapril Maleate 20mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>ferric oxide red</li>
<li>ferric oxide yellow</li>
<li>starch, corn</li>
<li>lactose</li>
<li>magnesium stearate</li>
<li>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></li>
<li>sodium stearate</li>
</ul>
<p><br></p>
<p>COLOR: pink</p>
<p><br></p>
<p>SHAPE: TRIANGLE</p>
<p><br></p>
<p>SCORE: Two even pieces</p>
<p><br></p>
<p>SIZE: 8 mm</p>
<p><br></p>
<p>IMPRINT: VASO;20</p>
<p><br></p>
<p>PACKAGING: 30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da4704d6-dc9e-4539-809e-4bdbc898043a&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da4704d6-dc9e-4539-809e-4bdbc898043a&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VASOTEC 		
					</strong><br><span class="contentTableReg">enalapril maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61786-168(NDC:0187-0143)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Enalapril Maleate</strong> (ENALAPRILAT ANHYDROUS) </td>
<td class="formItem">Enalapril Maleate</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VASO;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61786-168-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018998</td>
<td class="formItem">02/25/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fac94d81-773d-4bb7-b8b8-f6452314f095</div>
<div>Set id: da4704d6-dc9e-4539-809e-4bdbc898043a</div>
<div>Version: 1</div>
<div>Effective Time: 20150225</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
